MDH2 and ovarian carcinoma: Silencing MDH2 suppresses mitochondrial respiration and ovarian cancer cell proliferation, indicating that targeting ZDHHC18-mediated MDH2 palmitoylation represents a potential therapeutic strategy for EOC (135).